Biopsy Troubles | GenomeWeb

Biopsy Troubles

A personalized medicine study has run into an unexpected issue: tumor biopsies that aren't good enough to undergo genetic analysis, Stat News reports.

Between 10 percent and 20 percent of the needle biopsies collected for the National Cancer Institute MATCH trial, which began in August, are of poor quality and contain few tumor cells, it adds.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.